Therapeutic blockade of TNF in patients with SLE-promising or crazy?
about
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus ErythematosusPrimary biliary cirrhosis and the nuclear pore complex.A novel TLR2-triggered signalling crosstalk synergistically intensifies TNF-mediated IL-6 inductionTumor necrosis factor inhibitors - state of knowledge.In-/off-label use of biologic therapy in systemic lupus erythematosus.Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedsideBone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases.Neutralization of tumor necrosis factor bioactivity ameliorates urethane-induced pulmonary oncogenesis in mice.BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year.Human embryonic stem cell-derived mesenchymal cells preserve kidney function and extend lifespan in NZB/W F1 mouse model of lupus nephritisHistorical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor.Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity-a comprehensive review.Autoimmunity in 2012.Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.Pyoderma gangrenosum and systemic lupus erythematosus: a report of five cases and review of the literature.Biologic agents in the treatment of glomerulonephritides.Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects.Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.Biologics for the treatment of autoimmune renal diseases.TNF-alpha and annexin A2: inflammation in thrombotic primary antiphospholipid syndrome.Systemic lupus erythematosus diagnosis and management.Rhupus; unusual presentations.Anti-tumor necrosis factor α treatment of interferon-α-induced murine lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation.X-linked agammaglobulinemia presenting with secondary hemophagocytic syndrome: a case report.[Established medications : new areas of application].[Recombinant proteins or monoclonal antibodies: comparative properties and interest in systemic lupus erythematosus].Attenuation of nephritis in lupus-prone mice by thalidomide.Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha.iRhom2 promotes lupus nephritis through TNF-α and EGFR signaling.Is there a role for TNFα blockade in ANCA-associated vasculitis and glomerulonephritis?Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment.Hidradenitis suppurativa associated with systemic lupus erythematosus: A case report.TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus.
P2860
Q28088753-FAE85717-ED66-4BA8-9BAE-8C14D417EC94Q30415170-912DA2DF-4B40-4801-AC3D-C27EF7F71D03Q34011478-B0D0490A-C0B2-4E29-BF43-C1CC2D0D0DDAQ34974335-82DA2A76-4F70-4A3B-8D24-F41A014D7FDDQ35094536-FC4A51AA-F8F1-47A2-AE20-A016BA7895BDQ35309470-88BD17D3-2E92-40AB-9181-0A2F1BEEEE15Q35614331-13A0FDC2-F158-419A-B601-733865647543Q35669716-E7886088-EE7C-44EC-A5C6-46BD92F47563Q35768902-B59BD099-BD4C-4378-8FA9-0758F0549921Q36340132-83635A6A-419F-431A-91BE-A36E3A4E20D6Q37272142-8FCF2248-4042-4E14-A824-1646C581CD46Q38074354-503901A0-A997-4A31-AD66-CF08AD757061Q38131447-D76F3651-0A5E-4FE5-94B1-4090BBC72394Q38150110-1F22C7FD-030D-4956-9B1B-89E867B9964BQ38246968-F44C5BD5-69DF-42BF-AB4C-61076D45A0C2Q38514894-E0BF51FF-4DE4-4C90-AA63-FE981C56EBA6Q38663608-10D28ABD-7284-4E2C-B2DF-DD22ED27A323Q38748557-371CD374-51B2-4596-8433-1C5980BB382EQ38763327-12C35E94-865E-4FE7-9018-8AB24DFDFDECQ38972413-675E7F51-0A85-423B-A80E-79C07B07D75CQ39053129-8866908F-A4B2-4957-B410-69FC0A31FBEAQ40283710-4D2D3197-F3F2-40EA-A865-F16A68D93EC1Q41837557-418FDC16-5602-433F-BAB6-91925522B7EFQ43233485-FA43DAA3-9434-435A-BCF6-42B7EA52EFA2Q44480906-81AC24EE-E53C-4982-8C88-E555C4A11D9DQ45027602-0D9821C5-B036-4B93-AA6E-659B92DD0B44Q47220547-6F92DB24-3EB0-4900-9305-0D1AE4A97625Q48192268-F01561C9-C62F-4BFB-8A01-FF5F3DD733BBQ49709167-8C86D11D-B97C-4FBB-B06B-AF6956822B85Q51066095-D5CF2AC8-C8A3-4E6C-A095-088A27BD5D6BQ51136025-8036F27D-E2C5-48D2-81EA-A3ED63A4A999Q51164426-A84C4336-986E-4675-A31D-ECA913B1F616Q55294194-F9E0F042-D8DE-4860-B4C9-8BACB4FB6A91Q55379196-15312881-FE29-4184-881B-74FAEECBA46B
P2860
Therapeutic blockade of TNF in patients with SLE-promising or crazy?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic blockade of TNF in patients with SLE-promising or crazy?
@en
Therapeutic blockade of TNF in patients with SLE-promising or crazy?
@nl
type
label
Therapeutic blockade of TNF in patients with SLE-promising or crazy?
@en
Therapeutic blockade of TNF in patients with SLE-promising or crazy?
@nl
prefLabel
Therapeutic blockade of TNF in patients with SLE-promising or crazy?
@en
Therapeutic blockade of TNF in patients with SLE-promising or crazy?
@nl
P1433
P1476
Therapeutic blockade of TNF in patients with SLE-promising or crazy?
@en
P304
P356
10.1016/J.AUTREV.2011.05.001
P577
2011-05-18T00:00:00Z